Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

NCT ID: NCT00422877

Last Updated: 2025-10-16

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 13 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2008-03-31

Brief Summary

To evaluate objective response rate and duration of response to weekly Taxoprexin®.

To evaluate the safety profile of weekly Taxoprexin® in this patient population.

To evaluate overall survival in the same patient population.

To evaluate time to disease progression, and the time to treatment failure in patients with primary liver cancer being treated with weekly Taxoprexin® Injection.

To explore the trough and peak blood levels of Taxoprexin® and paclitaxel in these patients.

Detailed Description

This is a Phase II open-label study of weekly Taxoprexin® Injection in patients with advanced primary cancers of the liver, including hepatocellular carcinoma (HCC), or carcinoma of the gallbladder or biliary tract (BTC), who have not received prior systemic cytotoxic therapy for advanced disease. Patients may have previously received radiation and/or systemic chemotherapy as adjuvant therapy. Patients may not have been treated previously with a taxane. Patients may have been previously treated with up to two immunological and/or biologic agents (e.g., interferon, monoclonal antibodies, tyrosine kinase inhibitors). Patients will receive Taxoprexin® Injection at a dose of 500mg/m2 (400mg/m2 for patients with an elevated bilirubin at baseline) intravenously by 1-hour infusion weekly for the first five weeks of a six week cycle. Treatment will continue until progression of disease, intolerable toxicity, refusal of continued treatment by patient or Investigator decision.

Conditions

Cancer of the Liver

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Taxoprexin

Starting dose of 500 mg/m2 (400 mg/m2 for patients with an elevated bilirubin at baseline) administered intravenously by a 1-hour infusion weekly for the first 5 weeks of a 6 week cycle.

Group Type: EXPERIMENTAL

Taxoprexin

Intervention Type: DRUG

Administered by intravenous infusion over 1 hour infusion

Interventions

Taxoprexin

Administered by intravenous infusion over 1 hour infusion

Intervention Type: DRUG

Other Intervention Names

Docosahexaenoic acid (DHA)-paclitaxel

Eligibility Criteria

Inclusion Criteria

1. Patients must have histologic or cytologic confirmation of primary cancer of the liver, including HCC or adenocarcinoma of the gallbladder or bile ducts and advanced (unresectable and/or metastatic) disease.

2. Patients must have at least one measurable lesion by RECIST criteria.

3. Patients may have received up to two prior systemic non-cytotoxic regimens for their disease. Prior treatment with immunologic and/or biologic agents is allowed.

4. At least 6 weeks (42 days) since any prior immunologic or biologic therapy.

5. At least 4 weeks (28 days) since prior radiotherapy to >20% of the bone marrow or prior adjuvant chemotherapy.

6. Lesions being used to assess disease status may not have been radiated or if so, must have progressed during or after radiation therapy.

7. Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

8. Patients must be at least 18 years of age.

9. Patients must have adequate liver and renal function.

10. Patients must have adequate bone marrow function.

11. Patients must sign an informed consent form indicating that they are aware of the investigational nature of this study and in keeping with the policies of the institution.

Exclusion Criteria

1. Patients who have received prior therapy with any taxane.

2. Patients who have a past or current history of cancer other than the entry diagnosis, except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix or other cancers treated for cure and with a disease-free survival longer than 5 years.

3. Patients with symptomatic brain metastasis (es).

4. Patients who are pregnant or nursing and patients who are not practicing an acceptable method of birth control. Patients may not breastfeed while on this study.

5. Patients with active infections currently receiving anti-infectious treatment (e.g., antibiotics, antivirals, or antifungals).

6. Patients with current peripheral neuropathy of any etiology that is greater than grade one (1).

7. Patients with unstable or serious concurrent medical conditions are excluded.

8. Patients with a known hypersensitivity to Cremophor®.

9. Patients with one or more of the following as the only manifestations of disease are ineligible: bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, carcinomatous lymphangitis, central nervous system (CNS) metastases, lesions in a previously irradiated area that have not shown definite progression, or disease only inferred from laboratory tests or markers.

10. Patients with a history of Gilbert's Syndrome.

11. Patients must not receive any concurrent chemotherapy, radiotherapy, non-FDA approved nutritional supplements or herbal preparations or immunotherapy while on study.

12. Known HIV disease or infection.

13. Patients receiving ketoconazole, erythromycin, verapamil, diazepam, quinidine or diltiazem.

14. Patients must not have had any surgical procedure requiring hospitalization and administration of general anesthesia within the past 28 days.

15. Patients must not have received prior systemic chemotherapy for advanced disease. Prior adjuvant systematic chemotherapy (non-taxane containing) is allowed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

American Regent, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ahmed Kaseb, M.D.

Role: STUDY_DIRECTOR

M.D. Anderson Cancer Center

Locations

University of Texas, MD Anderson Cancer Center

Houston, Texas, United States

Countries

United States

Other Identifiers

P01-05-23

Identifier Type: -

Identifier Source: org_study_id